Ohio HB263 caps cost sharing for prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices.

Ohio HB263 enacts section 3902.65 of the Revised Code to limit cost sharing for prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices. It defines "prescription insulin drug" as a drug containing insulin used to treat diabetes, "diabetes device" as a blood glucose test, and "diabetic ketoacidosis device" as a device used to screen for or prevent diabetic ketoacidosis. The bill mandates that no health plan issuer can require cost sharing exceeding $35 for a 30-day supply of insulin drugs and $100 for diabetes or diabetic ketoacidosis devices.

Ohio HB263 caps cost sharing for prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices.

Ohio HB263 enacts section 3902.65 of the Revised Code to limit cost sharing for prescription insulin drugs, diabetes devices, and diabetic ketoacidosis devices. It defines "prescription insulin drug" as a drug containing insulin used to treat diabetes, "diabetes device" as a blood glucose test, and "diabetic ketoacidosis device" as a device used to screen for or prevent diabetic ketoacidosis. The bill mandates that no health plan issuer can require cost sharing exceeding $35 for a 30-day supply of insulin drugs and $100 for diabetes or diabetic ketoacidosis devices.